Evolus vs Ironwood Pharmaceuticals
Evolus and Ironwood Pharmaceuticals are similar in size: $297m and $296m of revenue in their latest fiscal years. Evolus grew faster (11.6% against -15.7%). Ironwood Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 8.1% against -17.4%.
| Latest fiscal year | EvolusEOLS, 2025 | Ironwood PharmaceuticalsIRWD, 2025 |
|---|---|---|
| Revenue | $297m | $296m |
| Revenue growth | 11.6% | -15.7% |
| Net income | −$51.6m | $24.0m |
| Operating margin | -11.0% | 33.3% |
| Net margin | -17.4% | 8.1% |
| Return on equity | — | — |
| Free cash flow | −$45.7m | $127m |
| Cash | $53.8m | $215m |
| Total debt | $150m | $585m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 334 | 100 |
| Market value | $481m | $582m |
| Price vs our value range | — | Below our value range |
| Moat score | 10 (Weak) | 31 (Weak) |
| Insider trades, 12 months | 0 buys, 7 sales | 0 buys, 18 sales |